

WO 02/060507

1/10

PCT/NL02/00065




Fig. 1

WO 02/060507

2/10

PCT/NL02/00065




Fig. 2

WO 02/060507

3/10

PCT/NL02/00065





Fig. 3

WO 02/060507

4/10

PCT/NL02/00065

Figure 4: Dissolution of biomimetic calcium phosphate coating in saline solution at pH 7.3 at 37°C. Calcium release as function of immersion time.




WO 02/060507

5/10

PCT/NL02/00065

Figure 5: Growth factor release as function of immersion time in saline solution at pH 7.3 and 37°C.




WO 02/060507

6/10

PCT/NL02/00065

Figure 6: Molecular structure of tobramycin




WO 02/060507

7/10

PCT/NL02/00065

Figure 7: Incorporation of tobramycin in the biomimetic CHA coating by using co-precipitation




WO 02/060507

8/10

PCT/NL02/00065

Figure 8: Adsorption of tobramycin on plasma sprayed calcium phosphate coating in different concentrated solution for 10, 40 minutes or 48 hours





WO 02/060507

9/10

PCT/NL02/00065

Figure 9: Inhibition zone for *staphylococcus aureus* bacteria growth observed around a titanium disc coated with the biomimetic CHA coating produced with 250 mg/l tobramycin in solution



WO 02/060507

10/10

PCT/NL02/00065

Figure 10: Colony forming units (CFU) per gram of bone around titanium implants coated with apatite coatings without or with tobramycin after injection of 10E6 CFU of staphylococcus aureus in the bone defect an dimplantation for 4 weeks in NZW rabbits.

